Rationally Repurposing Ruxolitinib (Jakafi®) as a Solid Tumor Therapeutic

Frontiers in Oncology - Switzerland
doi 10.3389/fonc.2016.00142
Full Text
Abstract

Available in full text

Date
Authors
Publisher

Frontiers Media SA

Related search

Tumor Evolution as a Therapeutic Target

Cancer Discovery
Oncology
2017English

EZH2 as a Therapeutic Target in Solid Tumors

Cancer Cell & Microenvironment
2015English

Drug Repurposing for Gastrointestinal Stromal Tumor

Molecular Cancer Therapeutics
Cancer ResearchOncology
2013English

Dll4-Notch Signaling as a Therapeutic Target in Tumor Angiogenesis

Vascular Cell
Computer NetworksDevelopmental NeuroscienceNeurologyCell BiologyCommunications
2011English

Ibrutinib Repurposing: From B-Cell Malignancies to Solid Tumors

Oncoscience
Cancer ResearchOncology
2016English

Clarithromycin as a “Repurposing Drug” Against MALT Lymphoma

British Journal of Haematology
Hematology
2017English

Tumor-Infiltrating Inflammatory Cells as Possible Therapeutic Targets

2012English

Ruxolitinib as an Emerging Treatment in Myelofibrosis

Blood and Lymphatic Cancer: Targets and Therapy
2013English

Drug Repurposing of Bromodomain Inhibitors as Potential Novel Therapeutic Leads for Lymphatic Filariasis Guided by Multispecies Transcriptomics

mSystems
EvolutionEcologyGeneticsMolecular BiologyBiochemistrySystematicsMicrobiologySimulationComputer Science ApplicationsBehaviorModelingPhysiology
2019English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy